BRPI0820856A2 - anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos - Google Patents

anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos

Info

Publication number
BRPI0820856A2
BRPI0820856A2 BRPI0820856-5A BRPI0820856A BRPI0820856A2 BR PI0820856 A2 BRPI0820856 A2 BR PI0820856A2 BR PI0820856 A BRPI0820856 A BR PI0820856A BR PI0820856 A2 BRPI0820856 A2 BR PI0820856A2
Authority
BR
Brazil
Prior art keywords
hedgehog
therapeutic applications
reaction series
reaction
series
Prior art date
Application number
BRPI0820856-5A
Other languages
English (en)
Inventor
John Thomas Russell
Pericot Mohr Gal.La
Minetto Giacomo
Cornelia Bakker Annette
Frruzzi Pietro
Original Assignee
Siena Bhiotech.S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siena Bhiotech.S.P.A. filed Critical Siena Bhiotech.S.P.A.
Publication of BRPI0820856A2 publication Critical patent/BRPI0820856A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

antagonistas da série de reação de hedgehog e aplicações terapêuticas dos mesmos a presente invenção refere-se aos compostos heterocíclicos que modulas a série de reação de hedgehog, à composição farmacêutica dos mesmos e pedidos terapêuticos dos mesmos.
BRPI0820856-5A 2007-12-13 2008-12-10 anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos BRPI0820856A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07024218 2007-12-13
EP07024218.5 2007-12-13
PCT/EP2008/010470 WO2009074300A2 (en) 2007-12-13 2008-12-10 Hedgehog pathway antagonists and therapeutic applications thereof

Publications (1)

Publication Number Publication Date
BRPI0820856A2 true BRPI0820856A2 (pt) 2019-05-14

Family

ID=39432963

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820856-5A BRPI0820856A2 (pt) 2007-12-13 2008-12-10 anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos

Country Status (16)

Country Link
US (1) US8592463B2 (pt)
EP (1) EP2227456A2 (pt)
JP (1) JP5620821B2 (pt)
CN (1) CN101896472A (pt)
AR (1) AR069652A1 (pt)
AU (1) AU2008335880B2 (pt)
BR (1) BRPI0820856A2 (pt)
CA (1) CA2709203A1 (pt)
CO (1) CO6210735A2 (pt)
CR (1) CR11481A (pt)
EA (1) EA017918B1 (pt)
IL (1) IL206298A0 (pt)
NZ (1) NZ586121A (pt)
TW (1) TW200930370A (pt)
WO (1) WO2009074300A2 (pt)
ZA (1) ZA201004185B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010126811A1 (en) * 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011084985A1 (en) 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
US9891149B2 (en) 2011-08-08 2018-02-13 Thermo Fisher Scientific Oy Method and apparatus for automated analysis
FI20115785A0 (fi) 2011-08-08 2011-08-08 Thermo Fisher Scientific Oy Menetelmä ja laite automaattiseen analyysiin
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
AU2012318874A1 (en) * 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
HK1221606A1 (zh) 2013-06-07 2017-06-09 加州生物医学研究所 纤维化的小分子抑制剂
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6706023B2 (ja) 2014-12-10 2020-06-03 ザ・スクリップス・リサーチ・インスティテュート 線維症の小分子阻害剤
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
WO2019062657A1 (zh) * 2017-09-30 2019-04-04 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110016054B (zh) * 2019-03-15 2021-10-22 四川大学 含磷氮苯并杂环结构的离子单体、用其阻燃的共聚酯型离聚物及它们的制备方法和应用
CN114790177B (zh) * 2021-01-26 2024-03-26 首都医科大学附属北京天坛医院 新型Hedgehog信号通路抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142917A0 (en) * 1998-11-03 2002-04-21 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
ATE369854T1 (de) * 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用

Also Published As

Publication number Publication date
JP5620821B2 (ja) 2014-11-05
CR11481A (es) 2010-10-15
WO2009074300A2 (en) 2009-06-18
US8592463B2 (en) 2013-11-26
CN101896472A (zh) 2010-11-24
CO6210735A2 (es) 2010-10-20
AR069652A1 (es) 2010-02-10
AU2008335880B2 (en) 2014-03-13
AU2008335880A1 (en) 2009-06-18
EA201000784A1 (ru) 2010-12-30
IL206298A0 (en) 2010-12-30
EA017918B1 (ru) 2013-04-30
WO2009074300A8 (en) 2009-11-19
WO2009074300A3 (en) 2009-10-01
EP2227456A2 (en) 2010-09-15
ZA201004185B (en) 2011-10-26
CA2709203A1 (en) 2009-06-18
JP2011506366A (ja) 2011-03-03
US20100286114A1 (en) 2010-11-11
TW200930370A (en) 2009-07-16
NZ586121A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
BRPI0820856A2 (pt) anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
CY1113122T1 (el) Μορφες δοσολογιας ανθεκτικες σε παραβιαση
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
FR2883179B1 (fr) Comprime enrobe
CL2007001674A1 (es) Compuestos derivados de heterociclos, inhibidores de aspartil proteasa; composicion farmaceutica que los comprende;y su uso para tratar enfermedades cardiovasculares,cognitivas y neurodegenerativas.
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
BR112012007747B8 (pt) compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
ECSP099320A (es) Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos
EP2114900A4 (en) COMPOUNDS ON THIOPYRIMIDINE BASE AND APPLICATIONS THEREOF
NO20084334L (no) Farmasoytiske sammensetninger
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
MX382815B (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
LTPA2015040I1 (lt) Vaistų farmakokinetinių savybių moduliatoriai
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
DK2343071T3 (da) Farmaceutiske doseringsformer
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
BRPI0815470A2 (pt) Distribuidor passivo de material volátil
BR112013000189A2 (pt) compostos de piridina anelados
BR112012032884A2 (pt) compostos e composições heteroarílicos como inibidores de quinase proteica
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]